Cracking the code: Delivering biotherapeutics successfully across EMEA
Learn how to optimize cold chain logistics for biotherapeutics in EMEA and overcome key challenges in delivery and regulation.
- Latest Posts
News and Trends 12 May 2025
Pharma giants pull back on AAV research: what’s next for the gene therapy space?
Biopharmas have been scaling back on AAV research for sometime now. Find out why and what’s on the horizon for drug delivery methods.
In Depth 9 May 2025
The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040
With one of the most densely concentrated life sciences hubs in Europe, the Netherlands sets its sights on becoming a global biotech leader.
Podcast 9 May 2025
Inside Flagship Pioneering’s strategy: How this VC turns ideas into biotech giants
In this episode Labiotech talks with Lovisa Afzelius, a General Partner at Flagship and uncovers the ways in which Flagship is shaking up the biotech funding model
In Depth 7 May 2025
Unlocking immunity: the power of TLR agonists
Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.
News and Trends 7 May 2025
Top biotech deals of April 2025
Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and drug delivery.
ADVERTISEMENT
ADVERTISEMENT
In Depth 6 May 2025
The future of diabetes treatment: Is a cure possible?
Diabetes has become an epidemic. Science is striving to find a diabetes treatment that can cure this chronic disease, but how close are we?
In Depth 5 May 2025
The biggest biotech funding rounds in April 2025
The companies Biohaven, MoonLake Immunotherapeutics, and AIRNA bagged the biggest biotech funding rounds overall in April 2025
Webinars 5 May 2025
AI in antibody discovery: From in silico analysis to AI-enabled data management
Explore how AI and bioinformatics are reshaping antibody discovery, from in silico design to efficient data management.
In Depth 2 May 2025
From pandemic spotlight to post-COVID crossroads: What happened to these biotech players?
Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article.
Podcast 2 May 2025
TCR-NK: A novel cell therapy transforming cancer treatment
Are TCR-NK treatments the next big thing in cell therapies for cancer patients? Find out in our talk with Namir Hassan, CEO of Zelluna.
In Depth 30 Apr 2025
The future of NSCLC treatment: what’s in store for the therapeutic space?
Here we delve into the different kinds of NSCLC therapies in the running to potentially address late-stage cancer that is often difficult to treat.
ADVERTISEMENT
